Steven C Derrick

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States Electronic address
    Vaccine 31:4641-6. 2013
  2. pmc Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis
    Steven C Derrick
    Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 7:e32959. 2012
  3. ncbi request reprint The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
    Cell Microbiol 9:1547-55. 2007
  4. pmc Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine
    Steven C Derrick
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Immunology 120:192-206. 2007
  5. doi request reprint The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 26:6092-8. 2008
  6. pmc Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant
    Kristopher Kolibab
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 17:793-801. 2010
  7. pmc Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Building 29 Room 511, CBER FDA, 29 Lincoln Dr, Bethesda, MD 20892, USA
    Infect Immun 73:7727-35. 2005
  8. ncbi request reprint Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responses
    Carol Goter-Robinson
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Building 29 Room 509, CBER FDA, 29 Lincoln Dr, Bethesda, MD 20892, USA
    Vaccine 24:3522-9. 2006
  9. pmc Early pulmonary cytokine and chemokine responses in mice immunized with three different vaccines against Mycobacterium tuberculosis determined by PCR array
    Jaehyun Lim
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 16:122-6. 2009
  10. pmc Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination
    Marcela Parra
    Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
    PLoS ONE 8:e66115. 2013

Collaborators

Detail Information

Publications21

  1. doi request reprint Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States Electronic address
    Vaccine 31:4641-6. 2013
    ..The identification of these highly immunogenic TB antigens and antigen combinations should allow for improved immunization strategies against tuberculosis...
  2. pmc Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis
    Steven C Derrick
    Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 7:e32959. 2012
    ..Overall, these data suggest that immunization with the ΔmmaA4BCG/adjuvant formulation may be an effective, safe, and relatively inexpensive alternative to vaccination with conventional BCG...
  3. ncbi request reprint The ESAT6 protein of Mycobacterium tuberculosis induces apoptosis of macrophages by activating caspase expression
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
    Cell Microbiol 9:1547-55. 2007
    ..Finally, experimental results using a cell impermeable fluorescent stain suggests that the formation of membrane pores may be a primary mechanism by which ESAT6 evokes an apoptotic response...
  4. pmc Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine
    Steven C Derrick
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Immunology 120:192-206. 2007
    ....
  5. doi request reprint The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
    Vaccine 26:6092-8. 2008
    ....
  6. pmc Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant
    Kristopher Kolibab
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 17:793-801. 2010
    ....
  7. pmc Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Building 29 Room 511, CBER FDA, 29 Lincoln Dr, Bethesda, MD 20892, USA
    Infect Immun 73:7727-35. 2005
    ..These data show that immunization with Sin85B offers protection similar to BCG in a murine model of pulmonary tuberculosis and suggest that Sin85B-induced protection is dependent upon both innate and acquired immune mechanisms...
  8. ncbi request reprint Protection against an aerogenic Mycobacterium tuberculosis infection in BCG-immunized and DNA-vaccinated mice is associated with early type I cytokine responses
    Carol Goter-Robinson
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Building 29 Room 509, CBER FDA, 29 Lincoln Dr, Bethesda, MD 20892, USA
    Vaccine 24:3522-9. 2006
    ..Taken together, these data suggest that the post-infection induction of early type 1 cytokine responses correlate with the induction of long-term protective immunity in vaccinated mice...
  9. pmc Early pulmonary cytokine and chemokine responses in mice immunized with three different vaccines against Mycobacterium tuberculosis determined by PCR array
    Jaehyun Lim
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
    Clin Vaccine Immunol 16:122-6. 2009
    ....
  10. pmc Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination
    Marcela Parra
    Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
    PLoS ONE 8:e66115. 2013
    ....
  11. pmc Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology Division of Veterinary Services, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 72:1685-92. 2004
    ..The substantial CD8-mediated protective immunity that was generated in the absence of CD4 cells suggests that it may be possible to develop effective TB vaccines for use in HIV-infected populations...
  12. pmc Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice
    Bo Young Jeon
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 76:5173-80. 2008
    ..tuberculosis strains in the mouse model of pulmonary tuberculosis and suggest that strain-specific resistance to BCG-induced protective immunity may be uncommon...
  13. ncbi request reprint A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Building 29, Room 502, CBER FDA, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Vaccine 23:780-8. 2004
    ....
  14. doi request reprint Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 29:2902-9. 2011
    ..These data support efforts to use MFT cell analyses as a measure of TB vaccine immunogenicity in human immunization studies...
  15. pmc Malaria infections do not compromise vaccine-induced immunity against tuberculosis in mice
    Marcela Parra
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Review, USFDA, Bethesda, Maryland, United States of America
    PLoS ONE 6:e28164. 2011
    ....
  16. doi request reprint Characterization of an intracellular ATP assay for evaluating the viability of live attenuated mycobacterial vaccine preparations
    Kristopher Kolibab
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, MD 20892, USA
    J Microbiol Methods 90:245-9. 2012
    ..Overall, these data indicate that the ATP luminescence assay is a rapid, sensitive, and reliable alternative method for quantifying the viability of varying live attenuated mycobacterial vaccine preparations...
  17. doi request reprint A practical in vitro growth inhibition assay for the evaluation of TB vaccines
    Kristopher Kolibab
    Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, United States
    Vaccine 28:317-22. 2009
    ..Overall, we have shown that a BSL-2 compatible in vitro growth inhibition assay using INH(r) BCG as the intra-macrophage target organism should be useful in developing and evaluating new TB immunization strategies...
  18. ncbi request reprint Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis
    Vasan K Sambandamurthy
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States
    Vaccine 24:6309-20. 2006
    ..tuberculosis. Given its overall safety and effectiveness, the mc(2)6030 live attenuated strain should be considered as a human vaccine candidate for protecting both healthy and HIV-infected individuals against TB...
  19. pmc Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis
    Vasan K Sambandamurthy
    Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Infect Immun 73:1196-203. 2005
    ....
  20. pmc Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis
    Joseph Hinchey
    Department of Microbiology and Immunology and Howard Hughes Medical Institute, Albert Einstein College of Medicine, New York, New York 10461, USA
    J Clin Invest 117:2279-88. 2007
    ..bovis bacille Calmette-Guérin vaccination. Our results define a mechanism for a key immune evasion strategy of M. tuberculosis and provide what we believe to be a novel approach for improving mycobacterial vaccines...
  21. pmc The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue
    Tsungda Hsu
    Howard Hughes Medical Institute, Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Proc Natl Acad Sci U S A 100:12420-5. 2003
    ..We conclude that the primary attenuating mechanism of bacillus Calmette-Guérin is the loss of cytolytic activity mediated by secreted ESAT-6, which results in reduced tissue invasiveness...